World Journal of *Clinical Cases*

World J Clin Cases 2022 February 16; 10(5): 1457-1753





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

Contents

Thrice Monthly Volume 10 Number 5 February 16, 2022

REVIEW

1457 Nonalcoholic fatty liver disease shows significant sex dimorphism Chen XY, Wang C, Huang YZ, Zhang LL

MINIREVIEWS

1473 Management of procedural pain in the intensive care unit

Guo NN, Wang HL, Zhao MY, Li JG, Liu HT, Zhang TX, Zhang XY, Chu YJ, Yu KJ, Wang CS

ORIGINAL ARTICLE

Clinical and Translational Research

1485 Effect of prior malignancy on the prognosis of gastric cancer and somatic mutation Yin X, He XK, Wu LY, Yan SX

Retrospective Cohort Study

1498 Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer

Chen ZX, Li J, Liu WB, Zhang SR, Sun H

Retrospective Study

1508 Timing theory continuous nursing, resistance training: Rehabilitation and mental health of caregivers and stroke patients with traumatic fractures

Shen YL, Zhang ZQ, Zhu LJ, Liu JH

1517 Effect of precise nursing service mode on postoperative urinary incontinence prevention in patients with prostate disease

Zheng XC, Luo TT, Cao DD, Cai WZ

Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and 1527 osteoporosis

Xie FF, Zhang YF, Hu YF, Xie YY, Wang XY, Wang SZ, Xie BQ

1536 Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key Zhou QY

Observational Study

1548 Correlation of myopia onset and progression with corneal biomechanical parameters in children Lu LL, Hu XJ, Yang Y, Xu S, Yang SY, Zhang CY, Zhao QY



World Journal of Clinical Cases

Contents

Thrice Monthly Volume 10 Number 5 February 16, 2022

META-ANALYSIS

Intensive vs non-intensive statin pretreatment before percutaneous coronary intervention in Chinese 1557 patients: A meta-analysis of randomized controlled trials

Yang X, Lan X, Zhang XL, Han ZL, Yan SM, Wang WX, Xu B, Ge WH

CASE REPORT

- 1572 Giant nodular fasciitis originating from the humeral periosteum: A case report Yu SL, Sun PL, Li J, Jia M, Gao HW
- 1580 Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report

Deng PB, Jiang J, Hu CP, Cao LM, Li M

1586 Submucosal protuberance caused by a fish bone in the absence of preoperative positive signs: A case report

Du WW, Huang T, Yang GD, Zhang J, Chen J, Wang YB

1592 Misdiagnosis of unroofed coronary sinus syndrome as an ostium primum atrial septal defect by echocardiography: A case report

Chen JL, Yu CG, Wang DJ, Chen HB

- 1598 Uncommon complication of nasoenteral feeding tube: A case report Jiang YP, Zhang S, Lin RH
- 1602 Treatment of extracranial internal carotid artery dissecting aneurysm with SUPERA stent implantation: Two case reports

Qiu MJ, Zhang BR, Song SJ

1609 Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report

Wang J, Gao YS, Xu K, Li XD

- 1617 Hemangioma in the lower labial vestibule of an eleven-year-old girl: A case report Aloyouny AY, Alfaifi AJ, Aladhyani SM, Alshalan AA, Alfayadh HM, Salem HM
- 1623 Primary orbital monophasic synovial sarcoma with calcification: A case report Ren MY, Li J, Li RM, Wu YX, Han RJ, Zhang C
- 1630 Small-cell carcinoma of the prostate with negative CD56, NSE, Syn, and CgA indicators: A case report Shi HJ, Fan ZN, Zhang JS, Xiong BB, Wang HF, Wang JS

1639 Disseminated peritoneal leiomyomatosis with malignant transformation involving right ureter: A case report

Wen CY, Lee HS, Lin JT, Yu CC



World Journal of Clinical Cases	
Conte	nts Thrice Monthly Volume 10 Number 5 February 16, 2022
1645	Arthroscopic surgery for synovial chondroma of the subacromial bursa with non-traumatic shoulder subluxation complications: Two case reports
	Tang XF, Qin YG, Shen XY, Chen B, Li YZ
1654	Wilkie's syndrome as a cause of anxiety-depressive disorder: A case report and review of literature
	Apostu RC, Chira L, Colcear D, Lebovici A, Nagy G, Scurtu RR, Drasovean R
1667	Gastric schwannoma misdiagnosed as gastrointestinal stromal tumor by ultrasonography before surgery: A case report
	Li QQ, Liu D
1675	Giant retroperitoneal lipoma presenting with abdominal distention: A case report and review of the literature
	Chen ZY, Chen XL, Yu Q, Fan QB
1684	Pneumothorax during retroperitoneal laparoscopic partial nephrectomy in a lupus nephritis patient: A case report
	Zhao Y, Xue XQ, Xia D, Xu WF, Liu GH, Xie Y, Ji ZG
1689	Bulbar conjunctival vascular lesion combined with spontaneous retrobulbar hematoma: A case report
	Lei JY, Wang H
1697	Hepatitis B virus in cerebrospinal fluid of a patient with purulent bacterial meningitis detected by multiplex-PCR: A case report
	Gao DQ, Hu YQ, Wang X, Zhang YZ
1702	Aseptic abscess in the abdominal wall accompanied by monoclonal gammopathy simulating the local recurrence of rectal cancer: A case report
	Yu Y, Feng YD, Zhang C, Li R, Tian DA, Huang HJ
1709	Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case reports
	Zhu WJ, Da YW, Chen H, Xu M, Lu Y, Di L, Duo JY
1716	Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report
	Zhang J, Liu MH, Gao X, Dong C, Li YX
1723	Unusual magnetic resonance imaging findings of brain and leptomeningeal metastasis in lung adenocarcinoma: A case report
	Li N, Wang YJ, Zhu FM, Deng ST
1729	Diffuse invasive signet ring cell carcinoma in total colorectum caused by ulcerative colitis: A case report and review of literature
	Zhang Z, Yu PF, Gu GL, Zhang YH, Wang YM, Dong ZW, Yang HR
1738	Neurothekeoma located in the hallux and axilla: Two case reports
	Huang WY, Zhang YQ, Yang XH



World Journal of Clinical Co		
Conten	Thrice Monthly Volume 10 Number 5 February 16, 2022	
1747	Subclavian artery stenting <i>via</i> bilateral radial artery access: Four case reports <i>Qiu T, Fu SQ, Deng XY, Chen M, Dai XY</i>	

Contents

Thrice Monthly Volume 10 Number 5 February 16, 2022

ABOUT COVER

Editorial Board Member of World Journal of Clinical Cases, Prashanth Panta, MDS, Reader (Associate Professor), Department of Oral Medicine and Radiology, Malla Reddy Institute of Dental Sciences, Suraram 500055, Telangana, India. maithreya.prashanth@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC's CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Lin-YnTong Wang, Production Department Director: Xiang Li, Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Clinical Cases	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 2307-8960 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
April 16, 2013	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Thrice Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2307-8960/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
February 16, 2022	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2022 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



W J C C World Journal C Clinical Cases

World Journal of

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2022 February 16; 10(5): 1716-1722

DOI: 10.12998/wjcc.v10.i5.1716

ISSN 2307-8960 (online)

CASE REPORT

Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report

Jie Zhang, Mei-Hong Liu, Xue Gao, Chang Dong, Yan-Xia Li

ORCID number: Jie Zhang 0000-0002-4244-5660; Mei-Hong Liu 0000-0002-0061-0373; Xue Gao 0000-0002-3894-7561; Chang Dong 0000-0001-5203-0891; Yan-Xia Li 0000-0002-1586-5352

Author contributions: Dong C and Zhang J reviewed the literature and contributed to manuscript drafting; Liu MH performed the collection and interpretation of the clinical data and material; Gao X analyzed and interpreted the pathological findings; Li YX was responsible for the revision of the manuscript for important intellectual content; all authors contributed to the manuscript and approved the final version to be submitted.

Informed consent statement:

Informed written consent was obtained from the patient's proxy for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Supported by the Dalian Municipal

Jie Zhang, Mei-Hong Liu, Chang Dong, Yan-Xia Li, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China

Xue Gao, Department of Pathology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China

Corresponding author: Chang Dong, MD, Associate Chief Physician, Associate Professor, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Xigang District, Dalian 116011, Liaoning Province, China. dongchang8793@163.com

Abstract

BACKGROUND

Vedolizumab, a newer class of integrin antagonist biological agents, has been applied to treat patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC), especially for patients who are refractory to traditional therapies and tumor necrosis factor antagonists. However, some rare but lifethreatening adverse effects warrant pharmacovigilance. We describe the first fatal case of vedolizumab-associated severe diffuse interstitial lung disease in China.

CASE SUMMARY

We present a case of new-onset diffuse parenchymal lung disease developing under treatment with vedolizumab in a patient with UC. After two doses of vedolizumab, he developed persistent fever and progressively worsening dyspnea. Extensive workups, including bronchoalveolar lavage, transbronchial lung biopsy and metagenomic next-generation sequencing, identified no infectious causes, and other potential causes (such as tumors and cardiogenic pulmonary edema) were also excluded. As a result, a diagnosis of vedolizumabrelated interstitial lung disease was established. Unfortunately, although corticosteroids and empiric antibiotics were administered, the patient eventually died of respiratory failure.

CONCLUSION

Vedolizumab-related interstitial lung disease in patients with UC is rare but potentially lethal. Gastroenterologists and pulmonologists should be aware of vedolizumab-related adverse drug reactions.



Science and Technology Innovation Foundation, No. 2020JJ27SN072.

Country/Territory of origin: China

Specialty type: Medicine, general and internal

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B, B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work nonnoncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creat ivecommons.org/Licenses/bync/4.0/

Received: October 11, 2021 Peer-review started: October 11, 2021 First decision: November 7, 2021 Revised: December 18, 2021 Accepted: January 5, 2022 Article in press: January 5, 2022 Published online: February 16, 2022

P-Reviewer: Nikolić M. Triantafillidis I S-Editor: Ma YJ L-Editor: A P-Editor: Ma YJ



Key Words: Vedolizumab; Adverse effects; Ulcerative colitis; Inflammatory bowel disease; Interstitial lung disease; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Vedolizumab is the treatment of choice for patients with moderate-to-severe ulcerative colitis who are refractory to tumor necrosis factor antagonists. However, some rare but potentially lethal drug-associated adverse effects warrant pharmacovigilance. We present a case of new-onset diffuse parenchymal lung disease development under treatment with vedolizumab in a patient with ulcerative colitis. After two doses of vedolizumab, he developed persistent fever, progressively worsening dyspnea and eventually died of respiratory failure. The patient was eventually diagnosed with vedolizumab-related interstitial lung disease, in spite of the few case reports found after reviewing the literature. We aim to raise gastroenterologists' and pulmonologists' vigilance to this uncommon adverse event.

Citation: Zhang J, Liu MH, Gao X, Dong C, Li YX. Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report. World J Clin Cases 2022; 10(5): 1716-1722

URL: https://www.wjgnet.com/2307-8960/full/v10/i5/1716.htm DOI: https://dx.doi.org/10.12998/wjcc.v10.i5.1716

INTRODUCTION

Vedolizumab is a fully humanized monoclonal antibody. It is currently the only intestinal selective biological agent in the field of inflammatory bowel disease (IBD) that targets $\alpha 4\beta 7$ gastrointestinal integrin receptors and blocks the receptor's interaction with mucosal addressin cell adhesion molecule-1, thereby inhibiting the migration of T lymphocytes into the intestinal parenchymal tissue in order to reduce inflammation[1]. In March 2020, vedolizumab produced by Takeda Pharmaceutical Company was approved for marketing in China for the first time. Although the clinical effectiveness of this brand has been continuously verified and recognized^[2], safety and adverse events have also attracted negative attention. Here, we describe one fatal case of vedolizumab-associated severe interstitial lung disease in a patient with ulcerative colitis (UC). We also reviewed the existing literature in English and found only seven case reports of vedolizumab-associated lung diseases, mainly in patients with IBD.

CASE PRESENTATION

Chief complaints

A 61-year-old Chinese male was initially admitted to the gastroenterology department of our hospital with chief complaints of recurrent abdominal pain, diarrhea, mucopurulent hematochezia and weight loss.

History of present illness

The patient was diagnosed with UC 12 years prior to admission, and he had been treated with multiple conventional therapies, including, oral and topical aminosalicylates, dexamethasone enema, oral corticosteroids, selective leukocyte absorption treatment and intestinal flora adjustment treatment. In spite of these treatments, he experienced frequent flare-ups and was admitted to the hospital 3 times over the past 9 mo. Due to these failed conventional therapies, the patient was administered adalimumab 160 mg by subcutaneous injection. However, the symptoms continued with 10 to 20 bowel movements daily, and the modified Truelove and Witts severity index suggested moderately to severely active UC. As a result, the patient was started on vedolizumab. After the first dose of vedolizumab (300 mg intravenous infusion), fever at 39 °C and fatigue occurred the next day. He was treated with intravenous



mezlocillin, foscarnet sodium, and ornidazole, but the fever persisted. The second dose of vedolizumab was administered 2 wk later, and the patient responded well regarding his intestinal symptoms; however, he presented with new-onset dyspnea at rest and nonproductive cough 2 d after the second vedolizumab treatment. Half a month later, the patient was admitted to the Department of Respiratory and Intensive Care Unit (RICU) due to severe dyspnea.

History of past illness

There was no significant medical history.

Physical examination

Upon arrival to the RICU, a body temperature of 36.8 degrees Celsius, a blood pressure of 128/90 mmHg, a heart rate of 97 beats/min, and a respiratory rate of 28 times/min were noted. The remaining physical examination was unremarkable except for diffuse inspiratory crackles in both lungs.

Laboratory examinations

Lab data revealed the following: white blood cells $11.10 \times 10^{\circ}/L$, neutrophils 68.6%, lymphocytes 23.2%, hemoglobin 130 g/L and platelets 328 × 10⁹/L. Serum C-reactive protein was increased at 111 mg/L (normal range ≤ 8 mg/L), erythrocyte sedimentation rate at 64 mm/h (normal range ≤ 15 mm/h), fecal calprotectin at 250.9 ug/g (normal range 0-50 ug/g) and procalcitonin was normal at 0.07 ng/mL (normal range ≤ 0.5 ng/mL). A fecal occult blood test showed positive occult blood with 0-1 white blood cells per high-power field. Stool cultures for Salmonella, Shigella and *Campylobacter* were all negative. Arterial blood gas analysis showed that pO₂was 41 mmHg breathing ambient air. Extensive microbiology assays (blood and sputum culture, 1,3-beta-D-glucan, galactomannan testing, aspergillus antibody, cryptococcal capsular polysaccharide antigen, mycoplasma antibody, human immunodeficiency virus antibody, cytomegalovirus, Epstein-Barr virus, A and B influenza virus PCR assays, and, antibodies of Toxoplasma gondii, rubella, herpes simplex virus and legionella) identified no infectious causes. Serologic examination included rheumatoid factor, antinuclear antibody panel, ds-DNA antibodies, anti-extractable nuclear antigen antibodies, myositis antibody panel, antineutrophil cytoplasmic antibody panel, and immunoglobulin, which were not elevated to pathologic levels. Cardiogenic pulmonary edema was excluded due to normal myocardial enzymes, Btype natriuretic peptide, echocardiogram and echocardiography. Some tumor markers, including, carcinoma embryonic antigen, cytokeratin 19 fragment and neuron-specific enolase, were increased at 7.68 ng/mL (normal range 0-5 ng/mL), 12.37 ng/mL (normal range 0-5 ng/mL) and 26.61 ng/mL (normal range 0-24 ng/mL), respectively, while alpha-fetoprotein and carcinoma antigen 125 and 199 were in the normal range. Bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB) were also performed. Cultures from the BAL were negative for bacteria, mycobacteria and fungi. Samples from the BAL and the peripheral blood were sent together for metagenomic next-generation sequencing (mNGS). This sequencing uses an untargeted DNA/RNA sequencing method to detect all potential pathogens, including, bacteria, fungi, viruses, and parasites^[3]. In brief, the negative results of both mNGS and multiple microbiological cultures together effectively excluded infection.

Imaging examinations

On high-resolution computed tomography (HRCT), new-onset diffuse infiltrates, interlobular thickening and fibrosis were noted compared to a HRCT from one month prior (Figure 1).

Pathology

On histopathology, irregular glandular structures in the hyperplastic fibrous tissue were noted with scattered lymphocytes infiltrated in the interstitium. Intranuclear vacuoles, nuclear fragmentation, binuclear cells were seen (Figure 2). No tumor cells were noted and immunohistochemistry showed that adenoid structures were positive for cytokeratin AE1/AE3; epithelial cells were positive for the epidermal growth factor receptor (EGFR), p53 and negative for vimentin; positive immunostaining for Ki67 in some larger epithelial cells accounted approximately 15%; negative immunostaining for desmin was detected.

Zaisbidene® WJCC | https://www.wjgnet.com




Figure 1 High-resolution computed tomography of the patient before and after vedolizumab administration. A and B: The lung window of the patient in the high-resolution computed tomography (HRCT) before vedolizumab administration was basically normal except for some scattered miliary nodules and localized emphysema; C and D: the lung window of the patient in the HRCT after two doses of vedolizumab administration showed the new-onset severe diffuse infiltrates, interlobular thickening and fibrosis.




Figure 2 Pathology of transbronchial lung biopsy. A: Irregular glandular structures in the hyperplastic fibrous tissue and infiltrated lymphocytes scattered throughout the interstitium were noted (H&E, x200); B: The glandular cavity was covered with single or stratified epithelium, the epithelial cells were cubic or polygonal, some of the cells had large nuclei and slightly dense chromatin. Intranuclear vacuoles, nuclear fragmentation and binuclear cells were noted. The focal gland cavity contains histiocytes, and the interstitium was infiltrated with scattered lymphocytes. No tumor cells were noted (H&E, x400).

FINAL DIAGNOSIS

A diagnosis of vedolizumab-associated interstitial lung disease was made. The Naranjo adverse drug reaction scale [4] was calculated to be 6 (causality: probable).

TREATMENT

Vedolizumab was discontinued, and the patient was started on methylprednisolone 80 mg/day. Three days later, intubation and mechanical ventilation was initiated due to refractory hypoxia. The anti-infective treatment was adjusted to linezolid, meropenem, caspofungin, compound sulfamethoxazole tablets and foscarnet sodium without any response.

Baishideng® WJCC | https://www.wjgnet.com

OUTCOME AND FOLLOW-UP

Unfortunately, after nine days of hospitalization, the patient died due to respiratory failure.

DISCUSSION

The efficacy and safety of vedolizumab in patients with moderate to severe IBD have been confirmed in several pivotal clinical trials[5,6]. An integrated study analyzed 2830 IBD patients who used vedolizumab from 2009 to 2013 and showed that vedolizumab did not increase their risk of infection or malignancy, and the most common adverse events were nasopharyngitis, abdominal pain, headache and joint pain[7]. However, in the past 4 years, 7 cases of noninfectious lung injury related to vedolizumab have been reported, including 4 cases of UC and 3 cases of CD. In 2017, Sudheer *et al*[8] first reported a 58-year-old white man with UC who developed acute respiratory distress syndrome requiring intubation and mechanical ventilation after receiving 3 doses of vedolizumab. By withholding vedolizumab and applying the steroid, the patient was successfully discharged home. Another case was described by Eva et al[9] of a 52-year-old female with UC who suffered from new onset dyspnea and dry cough with chest CT showing diffuse ground-glass opacities. She was being treated with intravenous vedolizumab every 8 weeks for 2 years. Laboratory work did not identify infection, and the pathology of TBLB showed small bronchiole injury with debris and accumulation of mononuclear cells, macrophages and histiocytes. The fact that a complete resolution of symptoms and radiographic abnormalities was achieved by discontinuation of vedolizumab without any other treatments highly suggested vedolizumab-induced lung toxicity. Another recently published case has a similar clinical course as ours. A 39-year-old male diagnosed with UC presented with acute severe interstitial lung injury while receiving vedolizumab treatment[10]. While vedolizumab cessation and systemic steroid administration helped this patient, our patient was refractory to his therapy and finally passed away. Cucinotta et al[11] reported the off-label use of vedolizumab in a 13-year-old child with UC, and after three doses of vedolizumab, the child developed a persistent cough that resolved after vedolizumab discontinuation.

Strictly speaking, drug-induced pulmonary toxicity is not an extraintestinal manifestation of IBD[9,12]. Even so, over half of interstitial lung disease and granulomatous lung disease cases in IBD patients are drug-related; therefore, more differential diagnoses are necessary [13]. On that basis, we also reviewed 3 case reports of patients with CD. They presented with dyspnea, dry cough or fever with new-onset abnormal chest CT results (including pulmonary nodules, ground-glass opacities, pulmonary infiltrates or pleural effusions) after receiving 3-4 doses of vedolizumab[14-16]. On histopathology, lung biopsies from all 3 cases revealed noncaseating granulomatous inflammation. In terms of clinical outcome, 2 patients were successfully treated with prednisone, 1 patient failed systemic steroid treatment but was responsive to infliximab treatment, and complete resolution of pulmonary disease was achieved in all three cases.

In our case, we made a diagnosis of vedolizumab-induced lung injury for the following reasons. First, the patient had no respiratory symptoms or interstitial changes on his previous chest CT, even though his UC was actively relapsing during the past 9 months. Second, the new symptoms following the application of vedolizumab and new-onset diffuse parenchymal changes on CT highly suggested an adverse drug reaction. Third, the resolution of intestinal symptoms and the evolution of respiratory injury occurring directly after the administration of vedolizumab may be attributed to the drug mechanism of vedolizumab itself. One study suggested that vedolizumab could induce an upregulation of $\beta 1$ expression on lymphocytes (which is an integrin component involved in pulmonary homing)[14], thereby facilitating the development of pulmonary inflammation and injury. Fourth, the abnormalities in the chest CT of our case were the most severe when compared to the above published cases. The reason our patient was not responsive to systemic corticosteroid treatment was due to the devastating damage of the lung tissue and the delay in time to a diagnosis. Last, in addition to conventional microbiological tests, we also utilized the advanced mNGS technique, which has a much higher sensitivity than that of conventional tests in mixed pulmonary infection diagnoses [17]. It has been reported that the sensitivity of mNGS for pathogen detection was 97.1%, with a negative predictive value of 94.1%[18]. Moreover, extensive anti-infective therapy aiming to cover all



possible pathogens was administered without any improvement of symptoms. All the facts discussed above basically excluded the possibility of infection. To the best of our knowledge, this is the first fatal case of vedolizumab-associated interstitial lung disease reported in China. There was an additional death reported in which a 70-yearold man with a UC flare was being treated with prednisone and vedolizumab, but this patient had previously had mild chronic shortness of breath with chest CT showing bilateral interstitial fibrosis before receiving vedolizumab; therefore, we cannot confirm that it was vedolizumab-related^[19].

CONCLUSION

Vedolizumab-related interstitial lung diseases in patients with IBD can be potentially fatal (as in our case presentation). Gastroenterologists and pulmonologists should raise their awareness regarding these cases. Timely diagnosis, early discontinuation of the offending drug and systemic corticosteroid treatment could prevent irreversible fibrosis.

REFERENCES

- Fischer A, Zundler S, Atreya R, Rath T, Voskens C, Hirschmann S, López-Posadas R, Watson A, Becker C, Schuler G, Neufert C, Atreya I, Neurath MF. Differential effects of α4β7 and GPR15 on the homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 2016; 65: 1642-1664 [PMID: 26209553 DOI: 10.1136/gutjnl-2015-310022]
- Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S; Vedolizumab Germany 2 Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016; 43: 1090-1102 [PMID: 27038247 DOI: 10.1111/apt.13594]
- 3 Gu W, Miller S, Chiu CY. Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection. Annu Rev Pathol 2019; 14: 319-338 [PMID: 30355154 DOI: 10.1146/annurev-pathmechdis-012418-012751]
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245 [PMID: 7249508 DOI: 10.1038/clpt.1981.154]
- Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]
- Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-721 [PMID: 23964933 DOI: 10.1056/NEJMoa1215739]
- Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66: 839-851 [PMID: 26893500 DOI: 10.1136/gutjnl-2015-311079
- 8 Nambiar S, Karippot A, Oliver T. Vedolizumab-Associated Acute Respiratory Distress Syndrome. Am J Ther 2018; 25: e592-e593 [PMID: 29189313 DOI: 10.1097/MJT.00000000000627]
- 9 De Backer E, Bode H, Baert F. New-Onset Diffuse Parenchymal Lung Disease in a 52-Year-Old Woman With Ulcerative Colitis. Gastroenterology 2020; 158: 478-479 [PMID: 31560891 DOI: 10.1053/j.gastro.2019.09.016]
- Rizos ED, Antonogiannaki EM, Chatzidakis A, Kallieri M, Tsilogianni Z, Manali ED, 10 Economopoulos N, Triantafyllou K, Papiris SA, Polymeros D. Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis. Eur J Gastroenterol Hepatol 2021 [PMID: 34074983 DOI: 10.1097/MEG.000000000002197]
- Cucinotta U, Dipasquale V, Costa S, Pellegrino S, Ramistella V, Romano C. Vedolizumab-11 associated pulmonary manifestations in children with ulcerative colitis. J Clin Pharm Ther 2021 [PMID: 34278581 DOI: 10.1111/jcpt.13494]
- 12 Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary manifestations of Crohn's disease. World J Gastroenterol 2014; 20: 133-141 [PMID: 24415866 DOI: 10.3748/wjg.v20.i1.133]
- Eliadou E, Moleiro J, Ribaldone DG, Astegiano M, Rothfuss K, Taxonera C, Ghalim F, Carbonnel F, 13 Verstockt B, Festa S, Maia L, Berrozpe A, Zagorowicz E, Savarino E, Ellul P, Vavricka SR, Calvo M, Koutroubakis I, Hoentjen F, Salazar LF, Callela F, Cañete Pizarro F, Soufleris K, Sonnenberg E, Cavicchi M, Wypych J, Hommel C, Ghiani A, Fiorino G; ECCO CONFER COMMITTEE. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. J Crohns Colitis 2020; 14: 480-489 [PMID: 31602473 DOI: 10.1093/ecco-jcc/jjz165]



- 14 Lissner D, Glauben R, Allers K, Sonnenberg E, Loddenkemper C, Schneider T, Siegmund B. Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab. Am J Gastroenterol 2018; 113: 146-148 [PMID: 29311733 DOI: 10.1038/ajg.2017.395]
- Myc LA, Girton MR, Stoler MH, Davis EM. Necrobiotic Pulmonary Nodules of Crohn's Disease in a 15 Patient Receiving Vedolizumab. Am J Respir Crit Care Med 2019; 199: e1-e2 [PMID: 30156859 DOI: 10.1164/rccm.201806-1056IM]
- Abu Shtaya A, Cohen S, Kogan Y, Shteinberg M, Sagool O. Crohn's Disease with Atypical Extra-16 Intestinal Manifestations Developing Under Treatment with Vedolizumab. Eur J Case Rep Intern Med 2021; 8: 002265 [PMID: 33768073 DOI: 10.12890/2021_002265]
- 17 Wang J, Han Y, Feng J. Metagenomic next-generation sequencing for mixed pulmonary infection diagnosis. BMC Pulm Med 2019; 19: 252 [PMID: 31856779 DOI: 10.1186/s12890-019-1022-4]
- 18 Fang X, Mei Q, Fan X, Zhu C, Yang T, Zhang L, Geng S, Pan A. Diagnostic Value of Metagenomic Next-Generation Sequencing for the Detection of Pathogens in Bronchoalveolar Lavage Fluid in Ventilator-Associated Pneumonia Patients. Front Microbiol 2020; 11: 599756 [PMID: 33335520 DOI: 10.3389/fmicb.2020.599756]
- 19 Collins HW, Frye JW. Interstitial Lung Disease in a 70-Year-Old Man with Ulcerative Colitis. ACG Case Rep J 2018; 5: e28 [PMID: 29670924 DOI: 10.14309/crj.2018.28]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

